Merck eye drug matches anti-VEGF in DME trial with safety caveats

Merck (MRK) reported one-year results from its BRUNELLO trial for remigromig, an investigational drug for diabetic macular edema (DME). Both doses met the primary endpoint, showing non-inferiority to ranibizumab in visual acuity improvement. However, adverse events related to proliferative diabetic retinopathy were more frequent with remigromig. Merck plans to discuss results with regulators and is conducting further analyses.

Original reporting
Published Oct 10, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$MRK
Neutral
high confidence
Mentioned
$MRK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MRKNeutralMed
01

Why it matters

The non‑inferior efficacy positions remigromig as a possible alternative to anti‑VEGF therapy, but safety signals may temper enthusiasm.

02

Market read

First disclosure of pivotal trial results for a major pharma player; could affect MRK stock and ophthalmology biotech sector.

03

What to watch

Potential for regulatory scrutiny over higher PDR rates and need for longer‑term data.

Relevance 8/10Novelty 8/10Timing: same-day release

Background

Merck presented the data at the American Academy of Ophthalmology meeting, highlighting its novel tri‑specific antibody.

Company-level read

Ticker impact

$MRKNeutralHigh confidence
Context

Merck reported Phase 2b/3 BRUNELLO trial data showing remigromig met primary endpoint with non‑inferior visual acuity gains versus ranibizumab.

Expected impact

potential modest pressure as investors weigh safety concerns against efficacy

Evidence & confidence

First‑time disclosure of pivotal trial results; efficacy is positive but safety signals may limit upside.

Market effects

May influence other ophthalmology biotech peers as a Wnt‑pathway approach gains data.

Limited to US biotech and pharma markets.

Modest, primarily affecting investors tracking ophthalmology drug pipelines.

Counterpoint

Safety concerns could outweigh efficacy, prompting a sell‑off if adverse events rise.

Key entities

  • Merck

    Pharmaceutical company conducting the trial.

  • remigromig

    Investigational tri‑specific antibody targeting the Wnt pathway.

Related articles

$MRKMed

Merck TroFuse-015 Phase 3 Meets Survival Endpoint — CASRAI

Merck announced that its Phase 3 trial of sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in patients with advanced gastroesophageal adenocarcinoma. The drug showed a statistically significant improvement in survival compared to physician's choice treatments, though secondary endpoints were not met. Full results will be presented at an upcoming medical meeting. Sac-TMT is not yet approved for any use.

$MRKHighAI 9/10

Merck Buys San Diego's Cidara Therapeutics for $9.2 Billion

Merck completed its $9.2 billion acquisition of Cidara Therapeutics, gaining control of CD388, an experimental flu drug. CD388 showed 76.1% efficacy in preventing flu in healthy adults in a Phase 2b trial, but further testing is needed for high-risk groups. Merck paid $221.50 per share for Cidara, with 85.96% of shares tendered. The FDA granted CD388 Breakthrough Therapy Designation, and Phase 3 trials are ongoing.

$MRKMedAI 8/10

Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma

Merck's phase 3 TroFuse-015 trial showed sacituzumab tirumotecan improved overall survival in pretreated gastroesophageal adenocarcinoma patients, meeting its primary endpoint. The trial enrolled 473 patients, comparing the drug to treatment of physician's choice. Secondary endpoints like progression-free survival were not met, but the drug's safety profile was consistent with prior studies. Merck plans to discuss the data with regulators and present it at an upcoming medical meeting.